MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Subfoveal choroidal neovascularisation

Drug Safety Update

 April 2016: Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw

July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection

NICE Guidance (see also drug specific links below)

 NG82: Age-related macular degeneration, January 2018.

Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF-A, VEGF-B and the placental growth factor. It is an option for treating neovascular (wet) age-related macular degeneration, diabetic macular oedema and macular oedema secondary to central retinal vein occulsion. It is for specialist use only and is used in accordance with NICE guidance.

Brolucizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby suppressing endothelial cell proliferation and inhibiting the growth of new vessels and decreasing vascular permeability. It is licensed for use in the treatment of neovascular (wet) age-related macular degeneration. It is for specialist use only and is prescribed according to criteria approved by NICE.

Ranibizumab is a vascular endothelial growth factor inhibitor used for the treatment of neovascular (wet) age-related macular degeneration, diabetic macular oedema and macular oedema due to retinal vein occlusion. It is for specialist use only and is prescribed according to criteria approved by NICE.

Verteporfin is licensed for use in the photodynamic treatment of wet age-related macular degeneration with a confirmed diagnosis of classic subfoveal choroidal neovascularisation. It is for specialist use only.